COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression

COMPASS Pathways has announced that positive data demonstrating the potential of COMP360 psilocybin therapy in anorexia nervosa and severe treatment-resistant depression has been presented at the Society of Biological Psychiatry Annual Meeting in New Orleans, from two investigator-initiated studies.

Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

📰 Weekly newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

Make an account
Category Press Release
Published in GlobeNewswire
Country United Kingdom

Companies Featured

COMPASS Pathways
COMPASS Pathways is a publicly listed company (NASDAQ) that aims to develop psilocybin for treatment-resistant depression (TRD) for which it has completed a successful Phase IIb trial. It has gone public and has received substantial investment from atai.

0 Comments
Inline Feedbacks
View all comments